Page 39 - Haematologica May 2020

BM niche dysregulation in MPN
or idiopathic primary myelofibrosis. Br J
Haematol. 2002;119(3):709-712.
66. Liu GM, Zhang LJ, Fu JZ, et al. Regulation of
Ruxolitinib on matrix metalloproteinase in JAK2V617F positive myeloroliferative neo- plasms cells. Zhonghua Xue Ye Xue Za Zhi. 2017;38(2):140-145.
67. Tadmor T, Bejar J, Attias D, et al. The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms. Am J Hematol. 2013;88(5):355-358.
68. McLornan DP, Yakoub-Agha I, Robin M, Chalandon Y, Harrison CN, Kroger N. State- of-the-art review: allogeneic stem cell trans- plantation for myelofibrosis in 2019. Haematologica. 2019;104(4):659-668.
69. Verstovsek S, Mesa RA, Gotlib J, et al. Long- term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-con- trolled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017;10(1):1-14.
70. Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term efficacy and safety in comfort- II, a phase 3 study comparing ruxolitinib with best available therapy for the treatment of myelofibrosis: 5-year final study results. Blood. 2015;126(23):59.
71. Verstovsek S, Vannucchi AM, Griesshammer M, et al. Ruxolitinib versus best available therapy in patients with poly- cythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica. 2016;101(7):821-829.
72. Passamonti F, Griesshammer M, Palandri F, et al. Ruxolitinib for the treatment of inade- quately controlled polycythaemia vera with- out splenomegaly (RESPONSE-2): a ran- domised, open-label, phase 3b study. Lancet Oncol. 2017;18(1):88-99.
73. Harrison CN, Mead AJ, Panchal A, et al. Ruxolitinib vs best available therapy for et intolerant or resistant to hydroxycarbamide. Blood. 2017;130(17):1889-1897.
74. Gunawan A, Harrington P, Garcia-Curto N, McLornan D, Radia D, Harrison C. Ruxolitinib for the Treatment of Essential Thrombocythemia. HemaSphere. 2018;2 (4):e56.
75. Harrison CN, McLornan DP. Current treat- ment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond. Hematology Am Soc Hematol Educ Program. 2017;2017(1):489-497.
76. Bose P, Gotlib J, Harrison CN, Verstovsek S. SOHO State-of-the-Art Update and Next Questions: MPN. Clin Lymphoma, Myeloma Leuk. 2018;18(1):1-12.
77. Tremblay D, Mascarenhas J. Pacritinib to treat myelofibrosis patients with thrombo- cytopenia. Expert Rev Hematol. 2018;11(9): 707-714.
78. Harrington PM, Harrison CN. Beyond JAK- 2: potential targets for myeloproliferative neoplasm therapy. Expert Rev Hematol. 2018;11(4):315-324.
79. Kremyanskaya M, Hoffman R, Mascarenhas J, et al. A Phase 2 Study of Cpi-0610, a Bromodomain and Extraterminal (BET) Inhibitor, in Patients with Myelofibrosis (MF). Blood. 2018;132(Suppl 1):5481.
80. Quintás-Cardama A, Kantarjian H, Estrov Z, Borthakur G, Cortes J, Verstovsek S. Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leuk Res. 2012;36(9):1124- 1127.
81. DeAngelo DJ, Tefferi A, Fiskus W, et al. A phase II trial of panobinostat, an orally avail- able deacetylase inhibitor (DACi), in patients with primary myelofibrosis (PMF),
post essential thrombocythemia (ET), and post polycythemia vera (PV) myelofibrosis. Blood. 2010;116(21):630.
82. Mesa RA, Vannucchi AM, Mead A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an inter- national, randomised, phase 3 trial. Lancet Haematol. 2017;4(5):e225-e236.
83. Mascarenhas J, Hoffman R, Talpaz M, et al. Pacritinib vs best available therapy, includ- ing ruxolitinib, in patients with myelofibro- sis: A randomized clinical trial. JAMA Oncol. 2018;4(5):652-659.
84. Mesa RA, Kiladjian JJ, Catalano JV, et al. Simplify-1: A phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor–naïve patients with myelofibrosis. J Clin Oncol. 2017;35(34):3844-3850.
85. Harrison CN, Vannucchi AM, Platzbecker U, et al. Momelotinib versus best available therapy in patients with myelofibrosis pre- viously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 2018;5(2):e73-e81.
86. Pardanani A, Harrison C, Cortes JE, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial. JAMA Oncol. 2015;1(5):643-651.
87. Harrison CN, Schaap N, Vannucchi AM, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treat- ed with ruxolitinib (JAKARTA-2): a single- arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 2017;4(7):e317-e324.
88. Harrison CN, Mesa RA, Jamieson C, et al. Case series of potential wernicke’s encephalopathy in patients treated with fedratinib. Blood. 2017;130(Suppl 1):4197.
89. Valentin R, Grabow S, Davids MS. The rise of apoptosis: Targeting apoptosis in hemato- logic malignancies. Blood. 2018;132(12): 1248-1264.
90. McArthur K, Chappaz S, Kile BT. Apoptosis in megakaryocytes and platelets: the life and death of a lineage. Blood. 2018;131(6):605- 610.
91. Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, et al. Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia. N Engl J Med. 2015;373 (10):920-928.
92. Tefferi A, Lasho TL, Begna KH, et al. A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. N Engl J Med. 2015;373(10):908-919.
93. Mascarenhas J, Komrokji RS, Cavo M, et al. Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels. Blood. 2018;132(Suppl 1):685.
94. Kuykendall A, Wan Y, Mascarenhas J, et al. Favorable overall survival of imetelstat-treat- ed relapsed/refractory myelofibrosis patients compared with closely matched real world data: PS1456. HemaSphere. 2019;3:669-670.
95. Mascarenhas J, Lu M, Kosiorek H, et al. Oral Idasanutlin in Patients with Polycythemia Vera. Blood. 2019;134(6):525-533.
96. Lu M, Xia L, Salama ME, Hoffman R. Combination Treatment with an MDM2 Antagonist and a BET Inhibitor Targets Both Myelofibrosis Hematopoietic Stem/ Progenitor Cells and Their Tumor
Promoting Microenvironment. Blood.
2017;130(Suppl 1):4225.
97. Kvasnicka HM, Thiele J, Bueso-Ramos CE,
et al. Ruxolitinib-Induced Modulation of Bone Marrow Microenvironment in Patients with Myelofibrosis Is Associated with Inflammatory Cytokine Levels. Blood. 2014;124(21):3182.
98. Hasserjian RP, Gotlib J, Cortes JE, et al. Effect Of Treatment With The JAK2-Selective Inhibitor Fedratinib (SAR302503) On Bone Marrow Histology In Patients With Myeloproliferative Neoplasms With Myelofibrosis. Jamieson CHM, ed. Blood. 2013;122(21):2823.
99. Jamieson C, Hasserjian R, Gotlib J, et al. Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibro- sis in patients with myelofibrosis. J Transl Med. 2015;13(1):294.
100.Verstovsek S, Mesa RA, Foltz LM, et al. PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks. Blood. 2015;126 (23):56.
101. Verstovsek S, Hasserjian RP, Pozdnyakova O, et al. PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study. Blood. 2018;132(Suppl 1):686.
102.Verstovsek S, Talpaz M, Wadleigh M, et al. A randomized, double blind phase 2 study of 3 different doses of prm-151 in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: S828. HemaSphere. 2019;3(S1):S829.
103. Tibes R, Mesa RA. Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies. J Hematol Oncol. 2014.
104. Sasaki K, Gotlib JR, Mesa RA, et al. Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. Leuk Lymphoma. 2015;56(7):2092-2097.
105. Gupta V, Koschmieder S, Harrison CN, et al. Phase 1b Dose-Escalation Study of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis. Blood. 2014;124(21):712.
106.Mesa RA, Tefferi A, Elliott MA, et al. A phase II trial of pirfenidone (5-methyl-1- phenyl-2-[1H]-pyridone), a novel anti- fibrosing agent, in myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;114(1):111-113.
107.
108.
Mascarenhas J, Li T, Sandy L, et al. Anti- transforming growth factor-β therapy in patients with myelofibrosis. Leuk Lymphoma. 2014;55(2):450-452.
Yue L, Bartenstein M, Zhao W, et al. Preclinical Efficacy of TGF-Beta Receptor I Kinase Inhibitor, Galunisertib, in Myelofibrosis. Blood. 2015;126(23):603.
109.Verstovsek S, Savona MR, Mesa RA, et al. A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofi- brosis. Br J Haematol. 2017;176(6):939-949.
110. Masarova L, Verstovsek S, Hidalgo-Lopez JE, et al. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018;132 (16):1664-1674.
111. Herlihy N, Harrison CN, McLornan DP. Exploitation of the neural-hematopoietic stem cell niche axis to treat myeloprolifera- tive neoplasms. Haematologica. 2019;104(4):639-641.
112. Drexler B, Passweg JR, Tzankov A, et al. The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myelopro-
haematologica | 2020; 105(5)
1199